SCHEMBL19213853

SCHEMBL19213853

c1ccc(-c2ccc(-n3c4ccc(-c5ccc6c(c5)c5ccccc5n6-c5ccc6c(c5)-c5cccc7cccc-6c57)cc4c4ccc5ccccc5c43)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE6D O43924 1/20 0.35
ATM Q13315 3/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
KDM4E B2RXH2 1/20 0.34
TSPO P30536 1/20 0.33
ALDH1A1 P00352 2/20 0.31
TSHR P16473 2/20 0.31
MAPK1 P28482 2/20 0.31
HSD17B10 Q99714 2/20 0.31
TP53 P04637 1/20 0.31
HPGD P15428 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
HIF1A Q16665 1/20 0.31
HDAC4 P56524 1/20 0.31
MEN1 O00255 1/20 0.31
APAF1 O14727 1/20 0.31
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19213854 1.00 PDE6D (0.35) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213855 0.97 PDE6D (0.34) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213857 0.97 PDE6D (0.34) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213679 0.97 ATM (0.38) PDE6DATML3MBTL1KDM4EALDH1A1
SCHEMBL19213676 0.97 ATM (0.38) PDE6DATML3MBTL1KDM4EALDH1A1
SCHEMBL19213844 0.97 PDE6D (0.36) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213846 0.97 PDE6D (0.36) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213850 0.96 ATM (0.35) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213845 0.96 ATM (0.35) PDE6DATML3MBTL1KDM4ETSPO
SCHEMBL19213834 0.96 ATM (0.35) PDE6DATML3MBTL1KDM4ETSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10170707-B2 Compound, material for organic electroluminescence element, organic electroluminescence element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2019-01-01 US disclosed
US-20180145265-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-05-24 US disclosed
US-20180145265-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2018-05-24 US disclosed
US-20170229661-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-08-10 US disclosed
US-20170229661-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170229661-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE RER1, LEF1, L1CAM PDE6D 2312/4885ATM 1590/4885L3MBTL1 223/4885
US-20180145265-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE RER1, LEF1, L1CAM PDE6D 2312/4885ATM 1590/4885L3MBTL1 223/4885
US-10170707-B2 Compound, material for organic electroluminescence element, organic electroluminescence element, and electronic device RER1, LEF1, L1CAM PDE6D 2312/4885ATM 1590/4885L3MBTL1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.